SCHEMBL336103

SCHEMBL336103

CCOC(=O)c1cn(CC)c2c(OCc3ccccc3)cccc2c1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.63
TSHR P16473 3/20 0.55
MAPK1 P28482 1/20 0.55
LMNA P02545 2/20 0.47
ALDH1A1 P00352 3/20 0.46
CNR2 P34972 2/20 0.46
CNR1 P21554 1/20 0.46
MAPT P10636 1/20 0.46
HTT P42858 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
HPGD P15428 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PPIA P62937 1/20 0.45
P2RX3 P56373 1/20 0.43
GABRA1 P14867 1/20 0.43
GABRB1 P18505 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6689642 0.85 TDP1 (0.56) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL335844 0.82 TDP1 (0.59) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL335272 0.79 TDP1 (0.70) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL4906828 0.78 LMNA (0.63) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL4181154 0.78 TSHR (0.57) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL14854429 0.77 TDP1 (0.53) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL6692156 0.76 CLEC4M (0.67) ALDH1A1MAPTKDM4EMEN1HPGD
SCHEMBL7056985 0.75 LMNA (0.69) TDP1TSHRMAPK1LMNAALDH1A1
SCHEMBL340937 0.75 HTT (0.69) TDP1TSHRMAPK1ALDH1A1MAPT
SCHEMBL11138813 0.74 LMNA (0.50) TDP1TSHRMAPK1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed
WO-2004101584-A1 MACROLIDES SUBSTITUTED AT THE 3-POSITION HAVING ANTIMICROBIAL ACTIVITY GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed
WO-2004101589-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 TDP1 2672/4885TSHR 1567/4885MAPK1 2104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.